Antibodies against tumor necrosis factor delta (april)
CA 2446734 A1 · Owner: Human Genome Sciences, Inc. · Inventors: Ruben, Steven M.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to antibodies and related molecules that immunospecifically bind to Tumor Necrosis Factor Delta (TNF-delta; APRIL). The present invention also relates to methods and compositions for detecting diagnosing, prognosing, treating, preventing or ameliorating a disease or , disorder associated with aberrant APRIL or APRIL receptor expression or aberrant function of APRIL or APRIL receptor comprising antibodies or , fragments thereof or related molecules, that immunospecifically bind to APRIL. In particular, the present invention further relates to methods and compositions for detecting, diagnosing prognosing, preventing, treating, or , ameliorating autoimmune …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 22, 2002. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended May 22, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 22, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.